Segment Information - Schedule of Financial Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Net sales	$ 4,135	$ 10,622	$ 13,846	$ 16,479
Gross profit	(3,078)	8,311	(572)	11,486
Direct expenses	35,454	45,409	113,899	121,799
Segment contribution	(38,532)	(37,098)	(114,471)	(110,313)
Indirect expenses	(32,886)	(47,996)	(71,386)	(16,205)
Income (loss) from operations	(5,646)	10,898	(43,085)	(94,108)
Components of other
Change in fair value of contingent consideration liability	(33,243)	(48,549)	(73,441)	(17,845)
Change in fair value of contingent stock consideration			415
Cell Therapy
Segment Reporting Information [Line Items]
Direct expenses	19,863	22,690	65,896	61,082
Segment contribution	(19,863)	(22,690)	(65,896)	(61,082)
Biobanking
Segment Reporting Information [Line Items]
Net sales	1,405	1,343	4,061	4,204
Gross profit	506	420	949	1,986
Direct expenses	432	505	1,314	1,499
Segment contribution	74	(85)	365	487
Degenerative Disease
Segment Reporting Information [Line Items]
Net sales	2,730	9,279	9,785	12,275
Gross profit	(3,584)	7,891	(1,521)	9,500
Direct expenses	3,194	2,601	7,832	6,765
Segment contribution	(6,778)	5,290	(9,353)	2,735
Other
Segment Reporting Information [Line Items]
Direct expenses	11,965	19,613	38,857	52,453
Segment contribution	(11,965)	(19,613)	(38,857)	(52,453)
Indirect expenses	(32,886)	(47,996)	(71,386)	(16,205)
Components of other
Change in fair value of contingent consideration liability	(33,243)	(48,549)	(73,441)	(17,845)
Change in fair value of contingent stock consideration	(196)		415
Amortization	553	553	1,640	1,640
Total other	$ (32,886)	$ (47,996)	$ (71,386)	$ (16,205)